In vitro safety pharmacology profiling: what else beyond hERG?

J Hamon, S Whitebread, V Techer-Etienne… - Future medicinal …, 2009 - Future Science
One of the main reasons for drug failures in clinical development, or postmarket launch, is
lacking or compromised safety margins at therapeutic doses. Organ toxicity with poorly …

[PDF][PDF] A high-throughput screening identifies MICU1 targeting compounds

…, M Sturlese, A De Mario, V Techer-Etienne… - Cell reports, 2020 - cell.com
Mitochondrial Ca 2+ uptake depends on the mitochondrial calcium uniporter (MCU) complex,
a highly selective channel of the inner mitochondrial membrane (IMM). Here, we screen a …

[HTML][HTML] Gene-signature-derived IC50s/EC50s reflect the potency of causative upstream targets and downstream phenotypes

…, M Koziczak-Holbro, AM Amati, V Techer-Etienne… - Scientific reports, 2020 - nature.com
Multiplexed gene-signature-based phenotypic assays are increasingly used for the
identification and profiling of small molecule-tool compounds and drugs. Here we introduce a …

Gene-signatures predict biologically relevant dose-response potencies in phenotypic assays

…, M Koziczak-Holbro, A Marco Amati, V Techer-Etienne… - bioRxiv, 2019 - biorxiv.org
Multiplexed gene-signature-based phenotypic assays are increasingly used for the
identification and profiling of small molecule-tool compounds and drugs. Here we introduce a …

II Integrated approaches of predIctIve toxIcology

L Urban, J Wang, D Bojanic, S Ward - Predictive Toxicology in Drug …, 2010 - cambridge.org
Keating and colleagues linked it to hERG (human ether-a-go-go-related gene) channel
inhibition 4. The importance of hERG in drug discovery comes from two considerations:(a) The …